Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
about
Amyloid-β and Astrocytes Interplay in Amyloid-β Related DisordersUpdate on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Use of proteomic analysis to monitor responses to biological therapies.Differential white matter connectivity in early mild cognitive impairment according to CSF biomarkersAlzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.Evidence from biomarkers and surrogate endpoints.Multiplex approaches in protein microarray technology.Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease.CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade.Towards preventive medicine. High-throughput methods from molecular biology are about to change daily clinical practice.Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.Genomic and Proteomic Biomarker Discovery in Neurological Disease.Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.What can biomarkers tell us about cognition in Parkinson's disease?Biomarkers in biological fluids for dementia with Lewy bodies.CSF p-Tau levels in the prediction of Alzheimer's disease.Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
P2860
Q26766934-3FD3E955-83D2-4839-BDDD-7843F87A6B71Q30845482-64F566A4-9F65-4117-B987-F50C443CD114Q33196034-2508D7E7-1A6A-475E-BD09-E9718BD14899Q35116529-F2B92517-437C-412C-82E9-10BEE26AFC47Q35126030-2A4BFC67-3915-46EA-8836-A0174E075C63Q36045330-4F1334D1-A472-4719-87FA-E0BC4207A7E6Q36227932-F96304A5-BA70-4242-96B6-A2CD6FCD3FC1Q36638759-E9478F9B-B904-463E-ABF3-1392C23666C9Q36851017-EF076E44-9051-4242-950A-DEAC3CDC1883Q36969281-FEB5478B-6071-40F1-93BE-77149E56757FQ37068847-42C8C933-4FFF-463D-92F6-2516E7DB0816Q37541706-B1DFF9D6-1896-48A7-8128-C5F35BF16283Q37800101-27CCD514-B76B-4684-9CED-608B1AD44BA2Q38206497-F8F8123C-3F52-475E-9F70-FB1B86F0283BQ38283550-635503E5-1B6A-49CE-ABA8-69EAC702C29DQ41845685-B647EE14-CD58-4FB4-ABBB-017A9E08285CQ50541374-3E525DE4-573D-4914-8CCC-328EA464FF50Q51944474-2FC6AAC9-0CC5-40C1-85C0-37F7E79C6E2D
P2860
Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Advances in the development of ...... to phosphorylated tau protein.
@ast
Advances in the development of ...... to phosphorylated tau protein.
@en
type
label
Advances in the development of ...... to phosphorylated tau protein.
@ast
Advances in the development of ...... to phosphorylated tau protein.
@en
prefLabel
Advances in the development of ...... to phosphorylated tau protein.
@ast
Advances in the development of ...... to phosphorylated tau protein.
@en
P921
P1476
Advances in the development of ...... to phosphorylated tau protein.
@en
P2093
Alexander Goernitz
Katharina Buerger
P304
P356
10.1016/S0361-9230(03)00087-X
P577
2003-08-01T00:00:00Z